Your body makes it already
MOTS-c is a peptide, a short chain of amino acids. Its genetic instructions sit in mitochondria, the small parts of cells that help turn fuel into energy. Researchers have measured it in human muscle and blood.
That gives us a place to begin, but “the body makes it” isn’t a safety test for an injected product. Measuring what’s naturally present and giving someone more are different experiments. A headline can make them sound much closer than they are.
The exercise result came from mice
The exercise study brings two kinds of work together. Researchers measured people’s own MOTS-c around exercise. In mice, they gave the peptide and saw better physical performance.
The mouse result matters to researchers. It doesn’t show that giving MOTS-c to people improves fitness, or that it replaces the other effects of exercise. The human part of the paper didn’t test those claims.
When a summary says “exercise mimetic”, meaning something meant to copy an effect of exercise, we’d keep that missing human test in mind. It’s an idea being explored, not a result a person can count on.
A human study plan isn’t a result
The published evidence covered here contains no trial showing that administered MOTS-c benefits people. A registered study in adults with prediabetes and extra weight plans to test its effects on insulin sensitivity, how well the body responds to insulin. As of September 30, 2026, the registry record had no results.
A registration tells us what researchers intend to test. It can’t tell us whether the treatment worked, whether the risks were acceptable or who might benefit. There’s no need to rush ahead of the findings.
The safety gap is still there
The FDA’s MOTS-c review found no human safety studies and missing basic animal safety tests. It also raised concern about possible immune reactions to injected peptides, including clumps or impurities. These are concerns and missing evidence, rather than measured side-effect rates in people.
MOTS-c has no FDA approval. On FDA’s page current as of April 22, 2026, its nomination for compounding is withdrawn. That isn’t clearance or a move to Category 1, and the safety concerns remain beside the entry.
Those U.S. records don’t answer Australian access questions. Our comparison also explains why MOTS-c’s fuel-use research isn’t a substitute for the growth hormone research behind the other names.